Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
3(25%)
Results Posted
20%(1 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_3
1
8%
Ph not_applicable
2
17%
Ph early_phase_1
1
8%
Ph phase_1
2
17%
Ph phase_2
1
8%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(5)
Terminated(2)
Other(2)

Detailed Status

Completed5
unknown2
Terminated2
Active, not recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (14.3%)
Phase 12 (28.6%)
Phase 21 (14.3%)
Phase 31 (14.3%)
N/A2 (28.6%)

Trials by Status

unknown217%
completed542%
recruiting18%
terminated217%
active_not_recruiting217%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
PROCEDURE
Total Trials
12